Drug Channels

FEBRUARY 21, 2023

As always, we have updated all market and industry data with the most current information available, including our annual analyses of the market positions of the largest pharmacies, specialty pharmacies, and PBMs. If you have any questions before purchasing a license to the report, please email me.

Pharmacy 97

Pharmacy Specialty Pharmacies Licensing Licensing 97

Drug Channels

MARCH 15, 2022

Licenses for our DCI reports are regularly purchased by nearly every company involved in the drug channel: pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, hospitals, buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and more.

Pharmacy 98

Pharmacy Specialty Pharmacies Licensing Licensing 98

The Pharma Data

OCTOBER 27, 2020

License-related fees (5). License-related fees (5). The BREEZE study (NCT03950739) seeks to evaluate 45 patients on a stable dose of Tyvaso after switching to our new dry powder inhaler (DPI) form of treprostinil, which we licensed from MannKind Corporation. .

FDA 40

FDA Production Licensing Licensing 40

Drug Channels

FEBRUARY 22, 2022

As always, we have updated all market and industry data with the most current information available, including our annual analyses of the market positions of the largest pharmacies, specialty pharmacies, and PBMs. This 2022 edition addresses COVID-19 and its ongoing impact on the pharmacy and PBM industries.

Pharmacy 96

Pharmacy Specialty Pharmacies Biosimilars Licensing 96

Drug Channels

OCTOBER 19, 2020

Channel Strategy for First Medical Product – A Look at Channel Considerations for Pharmacy vs. Medical Plus – Tailored Track Options Based on Company Size : Emerging/Small Companies – Infrastructure Set-Up, License Procurement and 3PL Contracting Mid-Large Companies – How Do I Think About My Portfolio Differently Based on Product Type?

Science 52

Science Specialty Pharmacies Pharmacy Licensing 52

Drug Channels

OCTOBER 10, 2023

reviews the evolving specialty pharmacy industry and discusses emerging challenges from direct distribution models that bypass wholesale distribution. The exhibits appear in all license versions. The PowerPoint file option is available only with the purchase of a corporate license.) and Section 6.4.3. A new Section 6.2.2.

Pharmaceuticals 40

Pharmaceuticals Specialty Pharmacies Pharmacy Biosimilars 40

The Pharma Data

NOVEMBER 20, 2020

Eiger licensed exclusive worldwide rights to lonafarnib from Merck, known as MSD outside of the United States and Canada. Merck will not receive any milestone payments for the development of lonafarnib for the treatment of Progeria, and has waived royalty obligations from Eiger for a specified quantity of lonafarnib.

FDA Approval 52

FDA Approval FDA Clinical Trials Disease 52